摘要
目的:探讨美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效。方法:选择我院收治的90例冠心病心力衰竭患者,按随机数字表法分为观察组与对照组,各45例。对照组给予常规方案治疗,观察组在对照组基础上给予美托洛尔(起始剂量12.5 mg/d,bid,po,根据患者的病情变化逐步增加剂量,但是每日用量不超过100 mg)联合曲美他嗪(60 mg,tid)治疗,比较两组临床疗效及心功能指标变化情况。结果:观察组治疗总有效率显著高于对照组,差异有统计学意义(P <0.05);观察组治疗后左室射血分数、左心室收缩末期内径以及左心室舒张末期内径指标变化情况显著优于对照组,差异有统计学意义(P <0.05)。结论 :美托洛尔联合曲美他嗪治疗冠心病心力衰竭疗效确切,可有效改善心功能,值得临床推广运用。
Objective: To investigate the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure. Methods: 90 patients with coronary heart disease and heart failure admitted to our hospital were randomly divided into observation group and control group,45 patients in each group. The patients in the control group were given conventional treatment, and the patients in the observation group were given metoprolol (initial dose of 12.5 mg/d, bid, po, gradually increasing the dose according to the patient’s condition, but the daily dose ≤ 100 mg) combined with trimetazidine (60 mg, tid) on the basis of the control group. The clinical efficacy and changes in cardiac function were compared between the two groups. Results: The total effective rate in the observation group was significantly higher than that in the control group (P<0.05). The changes in left ventricular ejection fraction, left ventricular end-systolic diameter and left ventricular end-diastolic diameter in the observation group were significantly better than those in the control group (P<0.05). Conclusion: Metoprolol combined with trimetazidine is effective in the treatment of coronary heart disease and heart failure, and can effectively improve cardiac function, which is worthy of clinical application.
作者
刘志英
赵利红
Liu Zhi-ying;Zhao Li-hong(Zhengzhou 15th People’s Hospital,Henan Zhengzhou 450041,China)
出处
《中国执业药师》
CAS
2018年第11期17-19,共3页
China Licensed Pharmacist
关键词
美托洛尔
曲美他嗪
冠心病
心力衰竭
Metoprolol
Trimetazidine
Coronary Heart Disease
Heart Failure
